Modipran is indicated for the treatment of- depressive illness bulimia nervosa obsessive compulsive disorder.
Fluoxetine has been shown to selectively inhibit the reuptake of serotonin at the presynaptic neuronal membrane which causes increased synaptic concentration of serotonin in the CNS. This result in numerous functional changes associated with enhanced serotonergic neurotransmission. Fluoxetine appears to have no effect on the reuptake of norepinephrine and dopamine and does not exhibit anticholinergic, antihistaminic or α1 adrenergic blocking activity at usual therapeutic doses.
Initial treatment : Recent studies suggest that 20 mg/day of Fluoxetine may be sufficient to obtain satisfactory antidepressant response. Consequently, a dose of 20 mg/day administered in the morning is recommended as the initial dose. A dose increase may be considered after several weeks if no clinical improvement is observed. Dosage above 20 mg/day, should be administered on a bid schedule (i.e. morning and noon) and should not exceed a maximum dose of 80 mg/day. As with other antidepressants, the full antidepressant effect may be delayed until 4 weeks of treatment or longer. As with many other medications, a lower or less frequent dosage should be used in patients with renal and/or hepatic impairment. A lower or less frequent dosage should also be considered for patients, such as elderly, with concurrent disease or on multiple medication. A recommended maximum dose for elderly patients is 60 mg per day. Maintenance treatment : It is generally agreed among expert psychopharmacologists that acute episode of depression requires several months or longer sustained pharmacologic therapy. Fluoxetine is also used in dosage of 60 mg daily for the management of bulimia nervosa. Use in children : The use of Fluoxetine in children is not recommended as safety and efficacy have not been established.
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
Gastrointestinal: Nausea, vomiting, dyspepsia, dry mouth, and diarrhoea. Neurological: Anxiety, nervousness, insomnia/ drowsiness and fatigue. Others : Excessive sweating, pruritus, skin rashes associated with liver, kidney and lung involvement. It has therefore been advised that Modipran therapy should be discontinued in any patient who develops a skin rash.
Fluoxetine Hydrochloride is contraindicated in patients known to be hypersensitive to it. Monoamine oxidase inhibitors : There have been reports of serious, sometimes fatal reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs and changes of mental status that include extreme agitation progressing to delirium and coma) in patients receiving Fluoxetine in combination with monoamine oxidase inhibitors (MAOIs), and in patients who have recently discontinued Fluoxetine and are then started on MAOIs. Some cases presented with features resembling neuroleptic malignant syndrome. Therefore, Fluoxetine should not be used in combination with MAOI, or within 14 days of discontinuing therapy with MAOI. Since Fluoxetine and its major metabolites have very long elimination half-lives, at least 5 weeks should be allowed after stopping Fluoxetine and before starting MAOI.
MAO inhibitors : Sometimes serious fatal reactions have been reported with concomitant use. Antidepressants : There have been greater than two fold increases of previously stable plasma levels of other antidepressants. Lithium : There have been reports of increased or decreased lithium levels when used concomitantly with Modipran. Antipsychotics : Elevation of blood levels of haloperidol and clozapine has been observed in patients receiving concomitant Modipran. Anticonvulsants : Patients on stable dose of phenytoin and carbamazepine have developed elevated plasma anticonvulsant concentrations and clinical anticonvulsant toxicity following initiation of concomitant fluoxetine treatment. CNS active drugs : Caution is advised if concomitant administration of Modipran is required.
As Modipran undergoes hepatic metabolism and renal excretion, it should be used with caution and in reduced doses in patients with impaired hepatic or renal function. Because of its epileptogenic effect, it should be used with caution in patients with epilepsy or a history of such disorders. Modipran may alter glycaemic control and therefore caution is also warranted in diabetic subjects. Depressed patients with suicidal tendencies should be carefully supervised during treatment. Modipran is not usually considered a suitable form of therapy for the depressive component of bipolar (manic depressive) illness as mania may be precipitated.